The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear₩127.96Fair value₩3,415.64Bull₩9,118.00
FairClose
52-week traded range
52W low ₩6,170.0052W high ₩20,900.00
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading above the consensus fair value
HLB PHARMACEUTICAL CO., LTD. closed at ₩6,630.00, 94.1% above the consensus fair value of ₩3,415.64 drawn from 9 valuation models.
Financial DNA score 36/100 — Average. P/E of 47.0x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
₩2,798.71
-57.8%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
₩3,476.83
-47.6%
√(22.5 × EPS × BVPS)
EPS=141, BVPS=3810.34 · outside Graham range (P/E 47, P/B 1.7) — asset-light, treat as a rough floor
Graham Formula
₩9,118.00
+37.5%
EPS × (8.5 + 2g) × 4.4 ÷ FD_Rate
g=20%, FD=3.3%
P/E Fair Value
₩2,820.00
-57.5%
EPS × 20x (sector P/E)
EPS=141, Sector P/E=20x
Peter Lynch (PEG)
₩4,230.00
-36.2%
EPS × Growth% (PEG = 1 is fair)
EPS=141, g=30%
EV/EBITDA
₩127.96
-98.1%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=1.06B
Book Value (P/B)
₩1,390.78
-79.0%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=3810.34, ROE=3.7%, g=6%, r=10%
Reverse DCF
₩6,630.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 18.7% | Historical: 46%
Margin of Safety
₩3,415.04
-48.5%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=4553.39, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.